BRIEF-Kalytera submits phase 2 study protocol to IRBS for cannabidiol

* Kalytera submits phase 2 study protocol to IRBS for cannabidiol in the prevention of graft versus host disease
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.